Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Thalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
2-methoxyestradiol
CASI Pharmaceuticals
Relapsed Multiple Myeloma
1 trial -
ALLO-605
Allogene Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
APO010
Allarity Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
AUTO2
Autolus GmbH
Multiple Myeloma
1 trial -
All-trans Retinoic Acid in combination with the KPD Regimen
The First People's Hospital of Lianyungang
Multiple Myeloma in Relapse
1 trial -
Anti-GPRC5D CAR-T cells infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma in Relapse
1 trial -
Autologous BCMA-targeting CAR T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma in Relapse
1 trial -
BCMA CAR-T
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma, Plasma Cell Leukemia
1 trial -
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
2 trials -
BCMA targeted prime CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
1 trial -
BeEAM
Teva Pharma GmbH
Multiple Myeloma
1 trial -
Bortezomib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
C-CAR088
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
2 trials -
CAR-BCMA T Cells
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
CAR-T treatment
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
CEP-18770
Teva Generics B.V
Multiple Myeloma
1 trial -
CEP-18770
Teva Pharma GmbH
Multiple Myeloma
2 trials -
CM336 Plus Isatuximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma (MM)
1 trial -
CT-011
United Therapeutics Europe Ltd
Multiple Myeloma
1 trial -
Carfilzomib 56 MG [Kyprolis]
Samsung Bioepis NL B.V.
Multiple Myeloma
1 trial -
Cyclophosphamide
Takeda
Multiple Myeloma
1 trial -
Darinaparson
Alaunos Therapeutics
Multiple Myeloma
1 trial -
Descartes-11
Cartesian Therapeutics
Multiple Myeloma
2 trials
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.